全文获取类型
收费全文 | 2055篇 |
免费 | 261篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 62篇 |
妇产科学 | 50篇 |
基础医学 | 156篇 |
口腔科学 | 4篇 |
临床医学 | 212篇 |
内科学 | 349篇 |
皮肤病学 | 18篇 |
神经病学 | 34篇 |
特种医学 | 22篇 |
外国民族医学 | 5篇 |
外科学 | 108篇 |
综合类 | 265篇 |
预防医学 | 72篇 |
眼科学 | 16篇 |
药学 | 387篇 |
2篇 | |
中国医学 | 92篇 |
肿瘤学 | 498篇 |
出版年
2024年 | 4篇 |
2023年 | 49篇 |
2022年 | 72篇 |
2021年 | 105篇 |
2020年 | 90篇 |
2019年 | 87篇 |
2018年 | 95篇 |
2017年 | 102篇 |
2016年 | 93篇 |
2015年 | 86篇 |
2014年 | 160篇 |
2013年 | 151篇 |
2012年 | 126篇 |
2011年 | 147篇 |
2010年 | 133篇 |
2009年 | 102篇 |
2008年 | 101篇 |
2007年 | 118篇 |
2006年 | 65篇 |
2005年 | 75篇 |
2004年 | 52篇 |
2003年 | 37篇 |
2002年 | 38篇 |
2001年 | 45篇 |
2000年 | 35篇 |
1999年 | 20篇 |
1998年 | 15篇 |
1997年 | 10篇 |
1996年 | 9篇 |
1995年 | 12篇 |
1994年 | 15篇 |
1993年 | 12篇 |
1992年 | 13篇 |
1991年 | 9篇 |
1990年 | 10篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1974年 | 1篇 |
排序方式: 共有2354条查询结果,搜索用时 93 毫秒
141.
目的探讨康艾注射液联合改良VAD方案治疗多发性骨髓瘤(MM)的疗效及毒副反应。方法52例初治MM患者根据治疗方案的不同分为两组.观察组29例采用康艾注射液联合改良VAD方案治疗;而对照组23例仅接受改良VAD方案治疗。结果观察组患者有效率稍高于对照组,但差异无统计学意义(P〉0.05)。观察组骨髓抑制、肺部感染及恶心呕吐的发生率均低于对照组,差异有统计学意义(P〈0.05)。观察组生活质量改善率高于对照组,差异有统计学意义(P〈0.05)。结论康艾注射液联合改良VAD方案治疗MM安全、有效,值得临床推广应用。 相似文献
142.
目的观察EAG预激化疗作为诱导缓解方案在治疗老年急性髓系白血病患者中的疗效。方法对应用EAG预激方案治疗的30例AML患者(≥60岁)的临床资料进行回顾性分析,包括完全缓解率、有效率、生存期以及不良反应。结果 EAG诱导缓解的有效率为70.0%(21/30),CR率为50.0%(15/30),中位无病生存期6.5个月;EAG预激化疗的主要不良反应为骨髓抑制期继发的感染、出血,调整方案后所有患者均能耐受。结论 EAG预激化疗作为诱导缓解方案适用于老年AML患者。 相似文献
143.
144.
145.
目的观察不同剂量沙利度胺联合化疗方案(VAD)治疗多发性骨髓瘤(MM)的临床疗效及不良反应。方法23例患者随机分为二组,分别以沙利度胺400800mg/d+VAD(A组)及沙利度胺50-200mg/d+VAD(B组)治疗。结果A组组部分缓解4例,进步2例,无效2例,总有效率75%。B组部分缓解6例,进步5例,无效4例,总有效率73.3%。副反应:皮疹、便秘、嗜睡、周围神经病变、深静脉栓塞的发生A组均明显高于B组。结论沙利度胺的剂量〈200mg/d较为合适,既可得到相应的疗效又可降低副反应。 相似文献
146.
Loïc de Pontual Yves Mathieu Christelle Golzio Marlne Rio Valrie Malan Nathalie Boddaert Christine Soufflet Capucine Picard Anne Durandy Angus Dobbie Delphine Heron Bertrand Isidor Jacques Motte Ruth Newburry‐Ecob Laurent Pasquier Marc Tardieu Graldine Viot Francis Jaubert Arnold Munnich Laurence Colleaux Michel Vekemans Heather Etchevers Stanislas Lyonnet Jeanne Amiel 《Human mutation》2009,30(4):669-676
147.
H. Tedesco-Silva M.I. Lorber C.E. Foster H.W. Sollinger R. Mendez D.B. Carvalho R. Shapiro P.R. Rajagopalan H. Mayer J. Slade B.D. Kahan for the FTYA clinical study group 《Clinical transplantation》2009,23(5):589-599
Abstract: This exploratory, multicenter, open-label study evaluated the efficacy and safety of FTY720, as a part of an immunosuppressive regimen, in combination with everolimus and steroids in de novo renal transplant recipients at increased risk of delayed graft function (DGF). Patients received FTY720 (5 mg) and everolimus (4 mg) 2–12 h pre-transplantation, followed by 2.5 mg/d FTY720 and concentration-controlled everolimus (4–8 ng/mL) post-transplant for 12 months. Induction therapy was prohibited. After enrollment of 56 of the planned 200 patients between 2000 and 2002, the recruitment was terminated. The primary endpoint, rate of graft loss, or death at three months was 15.4% and the biopsy-confirmed acute rejection was 42.3%. Death or graft loss at 12 months in the DGF and non-DGF arms was 36.0% and 25.9%, respectively. The mean estimated creatinine clearance at three months was 63 and 55 mL/min in the non-DGF and DGF groups, respectively, while at 12 months it was 56 mL/min in both the groups. Although there was no comparator arm, the results from this exploratory study (compared with data from other phases II and III trials) indicated no apparent benefits of FTY720-based regimens for prevention of acute rejection and preservation of renal function in renal transplant recipients at high risk of DGF. 相似文献
148.
Yang JS 《World journal of gastroenterology : WJG》2007,13(4):651-651
Recently, the paper by Wang et at published in World Journal of Gastroenterology has given rise to great interest of many researchers. It is well known that hepatoma is one of the lethal diseases with a high incidence in the world, especially in Asia. Radiotherapy is the main treatment modality of hepatoma in clinical practice. Unfortunately, intrinsic radiosensitivity of cancer cells is not fully understood, though a large number of papers on it are now available. Yang and colleagues 21 have developed the premature chromosome condensation technique for clinical radiotherapy of hepatoma. A precise and quick measurement of cell radiosensitivity can detect the highrisk results after exposure to a large dose. 相似文献
149.
de Koning BA Lindenbergh-Kortleve DJ Pieters R Büller HA Renes IB Einerhand AW 《Digestive diseases and sciences》2007,52(8):1814-1825
In the current study we aimed to gain insight into epithelial-mesenchymal cross-talk and progenitor compartment modulation
during doxorubicin (DOX)-induced mucositis in mice. Intestinal segments were collected on various days after DOX treatment.
DOX-induced damage at day 1–2 was characterized by increased epithelial proliferation and apoptosis and a decrease in the
expression of epithelial differentiation markers. Concurrently, T-cell factor-4 (TCF4) levels increased and the epithelial
differentiation enhancing factor, bone morphogenic protein-4 (BMP4), decreased. During severe damage (day 3), BMP4 levels
were significantly increased, which inversely correlated with epithelial proliferation. At the same time, the expression of
the epithelial differentiation markers was increasing again. At day 7, BMP4 levels were down-regulated, while the levels of
the epithelial differentiation markers and TCF4 were normalized again. These data suggest that in response to DOX-induced
damage, BMP4 and TCF4 are modulated in such a way that homeostasis of the progenitor compartment is partly preserved. 相似文献
150.